Stanford University enters licence agreement for EGF technology

Stanford University has entered into a licensing agreement with Madenco Biosciences to develop and commercialise patented epidermal growth factor (EGF) wound healing technology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circuit rejects Stanford Uni’s ‘abstract’ genetics patent

15 March 2021 Stanford University can’t patent a genetic testing method as it is based on “abstract mathematical calculations”, the US Court of Appeals for the Federal Circuit has ruled.

Americas

Tribal business settles Stanford opioid treatment clash

29 November 2022 Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.

More on this story

Americas

Fed Circuit rejects Stanford Uni’s ‘abstract’ genetics patent

15 March 2021 Stanford University can’t patent a genetic testing method as it is based on “abstract mathematical calculations”, the US Court of Appeals for the Federal Circuit has ruled.

Americas

Tribal business settles Stanford opioid treatment clash

29 November 2022 Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.

More on this story

Americas

Fed Circuit rejects Stanford Uni’s ‘abstract’ genetics patent

15 March 2021 Stanford University can’t patent a genetic testing method as it is based on “abstract mathematical calculations”, the US Court of Appeals for the Federal Circuit has ruled.

Americas

Tribal business settles Stanford opioid treatment clash

29 November 2022 Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

Stanford University enters licence agreement for EGF technology

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features